Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Galapagos Stock Is Falling Today

By Cory Renauer - Jul 15, 2021 at 3:20PM

Key Points

  • Galapagos investors betting on the company's Toledo program were let down by lackluster phase 1 trial results.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's new salt-inducable kinase inhibitor program is getting off to a rocky start.

What happened

Shares of Galapagos (GLPG -0.82%), a biopharmaceutical company, are under pressure following clinical trial readouts for a couple of new drug candidates in phase 1 studies. Disappointing results from the company's Toledo program pushed the stock 13.1% lower as of 3:52 p.m. EDT on Thursday.

So what 

Following the implosion of Jyseleca in the U.S., Galapagos has leaned on its early clinical-stage pipeline to get attention from investors. The company has invested heavily in the Toledo program, which is a series of new drug candidates that target salt inducible kinases.

Investor looking at stock charts.

Image source: Getty Images.

Galapagos stock is sliding today because the company reported disappointing data for the first clinical-stage candidate to emerge from the Toledo program. After six weeks of treatment, rheumatoid arthritis patients randomized to receive GLPG3970 weren't any better off than the placebo group.

Ulcerative colitis patients who received GLPG3970 improved their Mayo Clinic Score, a measurement of disease severity, by 2.7 points on average. Unfortunately, the placebo group's score improved by 2.6 points.

If there's a future for GLPG3970 it's as a treatment for psoriasis. Four out of 13 psoriasis patients treated with GLPG3970 showed an improvement of 50% or better compared to none of the patients who received a placebo.

Galapagos also reported top-line results from a psoriasis study with GLPG3667, a selective TYK compound. After four weeks, treatment with GLPG3667 led to a 50% improvement or better for four out of 10 patients given a high dosage. None of the patients in the low-dose cohort achieved a 50% improvement.

Now what

Fairly positive psoriasis data is better than nothing, but neither of these new drug candidates looks like they have what it takes to eventually succeed in a commercial setting. Skyrizi, a successful psoriasis treatment AbbVie launched in 2019 led to 90% improvements for 75% of patients treated in clinical trials leading to its approval.

After watching Galapagos stock lose about 70% of its value over the past year, contrarian investors might be thinking about catching this falling knife. Considering the number of disappointments this company has already delivered, it's probably best to watch its story play out from a safe distance.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Galapagos Stock Quote
$54.17 (-0.82%) $0.45
AbbVie Inc. Stock Quote
AbbVie Inc.
$142.08 (0.81%) $1.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.